李真宝，男，1988年生，药剂学博士，研究员，安中学者杰出人才，青年皖江学者，中华中医药学会青年托举人才，安徽省教育厅优青、博士生导师/博士后合作导师，主要研究方向：中药制剂研发和智能纳米药物递送，聚焦于类风湿和肿瘤疾病模型，招收药剂学、药学专硕和中药学博士。以第一/通讯在Journal of Controlled Release, Biomaterials, Chinese Chemical Letters, Journal of Pharmaceutical Analysis, Asian Journal of Pharmaceutical Sciences, Small等期刊发表SCI论文20余篇（篇均IF>8）；主持国家自然科学基金3项，教育厅项目4项，申请国家发明专利12项，授权5项，专利转让1项（43万元）；担任Asian Journal of Pharmaceutical Sciences（中科院一区）、Journal of Pharmaceutical Analysis（中科院一区）、Journal of Traditional Chinese Medicine、Acta Materia Medica、Frontiers in Drug Delivery、Chinese Medicine、Integrative Medicine Discovery、Biomaterials Translational、《药物评价研究》和《食品研究与开发》青年编委，获得安徽省自然科学三等奖、安徽省D类人才、安徽省优秀青年研究生导师，合肥市D类人才，新站区第三季奋斗者、中国科技期刊卓越行动计划2021年度优秀审稿人、Asian Journal of Pharmaceutical Sciences优秀青年编委，AMM期刊2022年度优秀审稿人，国家自然科学基金评审专家，凡科优秀评审专家等荣誉称号。团队现处于高速发展期，仪器平台先进，长期招收科研助理、硕士、博士和博士后，欢迎有理想，有志气，踏实做科研的研究生加盟课题组。
1、主要学术任职
1. 2019.4 -至今 Asian Journal of Pharmaceutical Sciences青年编委
2. 2019.10-至今 《药物评价研究》青年编委
3. 2021.1-至今 Journal of Pharmaceutical Analysis青年编委
4. 2021.1-至今 Acta Materia Medica青年编委
5. 2022.9-至今 Journal of Traditional Chinese Medicine青年编委
6. 2022.10-至今 Frontiers in Drug Delivery review editor和编委
7. 2022.10-至今 Chinese Medicine青年编委
8. 2024.5-至今 Integrative Medicine Discovery青年编委
9. 2024.1-至今 Biomaterials Translational 青年编委
10. 2024.10-至今 《食品研究与开发》青年编委
2、近5年来主持科研项目情况
1. 国家自然科学基金面上项目1，49万，在研，主持
2. 安中学者杰出人才项目，300万，在研，主持
3. 国家自然科学基金面上项目2，49万，在研，主持
4. 安徽省高等学校优秀青年科研项目，50万，在研，主持
5. 西南特色中药资源国家重点实验室开放基金，10万，在研，主持
6. 中医药防治肺系重大疾病应用转化安徽省重点实验室开放课题，10万，在研，主持
7. 2022-2024年度中华中医药学会青年人才托举工程项目，结题，主持
8. 安徽省2021年青年皖江学者项目，50万，结题，主持
9. 国家自然科学基金青年项目，24万，结题，主持
10. 安徽省高等学校自然科学研究项目，6万，结题，主持
3、近年来发表有代表性学术论文、专著或教材
1. Yudi Lu, Mei Zhou, Xunfa Zhang, Weijun Huang, Fan Li, Ningli Zhang, Nannan Lu, Chenggui Wu, Zhihui Feng∗, Shuangying Gui∗, Zhenbao Li∗, Carrier-free reduction-responsive self-assembling paclitaxel dimer nanoprodrug synergizing with Celastrol for enhanced chemoimmunotherapy, Asian Journal of Pharmaceutical Sciences, 2026, 21 (2026) 101124.
2. Dian Jiao, Tao Wang, Yinghou Wang, Zhengdi Ma , Mingjia Sun, Chen Meng, Weihua Chen, Yaqi Wang, Yanxin Li, Yaru Song, Xinnan Hou, Zhong Wen, Jingdong Xiao, Zhonggui He, Tianhong Zhang*, Jin Sun *, Zhenbao Li*, Qikun Jiang*, Structure-Activity Optimization of Aliphatic Alcohol-Modified Camptothecin Prodrug-Albumin Nanoparticles Demonstrates Inverted V-shaped Albumin Binding and CES1/CES2-mediated Enzymatic Cascade Conversion, Cell Reports Physical Science, 2026, in press.
3. Yaqi Li, Yixin Sun, Qinglong Yan, Wenjing Wang, Shuo Wang, Qing Wang, Danping Wang, Jun Yuan, Jin Sun, Zhonggui He, Zhenbao Li*, Bingjun Sun*, Redox-triggered prodrug nanoassemblies with high tumor selectivity and biocompatibility break through antitumor dilemma of paclitaxel, Chinese Chemical Letters, 2026, 37 (2026) 111350.
4. Changlin Li, Xuan Liu, Tao Shao, Guodang Chen, Jingran Xuan, Dong Wang, Zhenbao Li*, Zhihui Feng*, Rational engineering of a Schiff base-iridium(III) complex for enhanced photodynamic therapy, Dalton Transactions, 2026 Feb 10;55(6):2533-2541.
5. Fan Li, Wenrui Wang, Weisheng Xu, WanYing Li, Yudi Lu, Rui Wang, Zhonggui He, Zhihui Feng*, Jiabing Tong*, Zhenbao Li*, Traditional Chinese medicine-facilitated Redox-labile Paclitaxel Dimer Nanoprodrug for Efficient Chemoimmunotherapy, Journal of Pharmaceutical Analysis, 2025;15(9):101348.
6. Qing Wang, Shiyi Zuo, Xixuan Yang, Yaqi Li, Cuiyun Liu, Yaqiao Li, Shuo Wang, Wenjing Wang, Danping Wang, Jiayu Guo, Jin Sun, Zhonggui He, Zhenbao Li*, Bingjun Sun*, Prodrug nanoassembly technology for colorectal cancer therapy, Biomedical Technology, 2025, 12 (2025) 100114.
7. Xue Zhang, Xingpai Cai, Tingting Zhang, Zhuzhen Chen, Wangxing Cheng, Zhenbao Li *, Linwei Chen *, Nannan Lu*, Signal amplifiation platform based on 2D MOF-on-MOF architectures-derived Co-decorated carbon@nitrogen-doped porous carbon for enhanced electrochemical acetaminophen sensing, Electrochimica Acta, 2025, 509 (2025) 145311.
8. Yu Cao, Yimin Ding, Xue Zhang, Shihan Kang, Wangxing Cheng, Zhenbao Li*, Linwei Chen *, Nannan Lu *, MOF-assisted synthesis of atomically dispersed Fe on N-doped porous carbon for enhanced electrochemical detection of chlorogenic acid, Microchemical Journal, 2025, 215 (2025) 114395.
9. Xia Wu, Weijun Huang, Mei Zhou, Nannan Lu*, Zhenbao Li*, Carrier-free nanodrugs for rheumatoid arthritis treatment, Integrative Medicine Discovery, 2024, 8:e24029.
10. Wenjing Zhang, Yuan Huang, Jing Li, Mei Zhou, Weijun Huang, Li Sun*, Shuangying Gui*, and Zhenbao Li*, Carrier-free poly(glycyrrhetinic acid)-facilitated celastrol-loaded nanoparticle for high-efficiency low-toxicity treatment of rheumatoid arthritis, Materials & Design, 2024, 241:112951.
11. Weimin Jin, Houyuan Yang, Miaomiao Zhang, Zegeng Li, Nianxia Sun, Zhili Han, Chenglin Shu, Zhenbao Li*, Dianlei Wang*, Inhalable cyclodextrin metal-organic framework dry powder enhanced direct pulmonary delivery of paclitaxel for the treatment of lung cancer, Journal of Drug Delivery Science and Technology, 2024, 101 (2024) 106310.
12. Wenjing Zhang, Yang Chen, Qin Liu, Mei Zhou, Kang Wang, Yongzhong Wang, Jiusheng Nie*, Shuangying Gui*, Daiyin Peng, Zhonggui He, Zhenbao Li*. Emerging nanotherapeutics alleviating rheumatoid arthritis by readjusting the seeds and soils, Journal of controlled release, 2022, 345:851-879.
13. Xunfa Zhang, Yang Chen, Xian He, Yachao Zhang, Mei Zhou, Chengjun Peng, Zhonggui He, Shuangying Gui*, Zhenbao Li*, Smart Nanogatekeepers for Tumor Theranostics, Small, 2021, 47:e2103712.
14. Yachao Zhang, Wenjing Zhang, Yongqi Wang, Jiaojiao Zhu, Mei Zhou, Can Peng, Zhonggui He, Jin Sun, Zhenbao Li*, Shuangying Gui*. Emerging nanotaxanes for cancer therapy. Biomaterials, 2021, 272:120790.
15. Kang Wang, Zhi Li, Yiming Huang, YaotianTao, Xiao Liang, Xiaoqin Chu, Ning He, Shuangying Gui, Zhenbao Li*，Additives-directed lyotropic liquid crystals architecture: Simulations and experiments，International Journal of Pharmaceutics, 2021, 600:120353.
4、指导研究生情况
指导毕业研究生8名，在读博士后1名，博士生3名，研究生7名，科研助理2名。
5、联系方式（电话、邮箱等）
联系邮箱：lizhenbao@ahtcm.edu.cn
联系电话：0551-68129366
办公地点：药学院555
